Xu Zhenyu sold $32K of SOPH

Xu Zhenyu (Chief Scientific Officer) sold 4,000 shares of SOPHiA GENETICS SA (SOPH) at $7.96 on 2026-11-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Xu Zhenyu
Published Nov 16, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
medium confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

Because the sale is pre-arranged, it typically has lower informational content than discretionary selling. Traders may still monitor for patterns, but this single transaction alone is unlikely to change SOPH’s fundamental outlook.

02

Market read

A disclosed insider sale provides a small sentiment datapoint, but no new business, financial, or regulatory information is presented.

03

What to watch

The article does not disclose whether other insiders sold/bought around the same time, nor does it provide context on total insider holdings beyond the post-transaction figure.

Relevance 2/10Novelty 2/10Timing: filed 2026-11-16, transaction dated 2026-11-13

Background

The filing is an SEC Form 4 insider transaction by SOPHiA Genetics CSO Xu Zhenyu, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$SOPHNeutralMedium confidence
Context

Insider Form 4 shows CSO Xu Zhenyu sold 4,000 shares of SOPHiA Genetics at $7.9553 on 2026-11-13 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact, with any effect driven by trader interpretation of insider selling rather than new company fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, and the disclosed size is modest relative to typical large-cap price-setting flows.

Market effects

Minimal, as this is company-specific insider trading with no disclosed operational or regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with management’s view of near-term valuation risk, so some traders may treat it as a mild bearish signal.

Key entities

  • SOPHiA GENETICS SA

    Company whose shares were sold by an insider under a Rule 10b5-1 plan.

  • Xu Zhenyu

    Chief Scientific Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September